Drug-Eluting Porous Embolic Microspheres for Trans-Arterial Delivery of Dual Synergistic Anticancer Therapy for the Treatment of Liver Cancer

Keyphrases

• Liver Cancer 100%
• Doxorubicin 100%
• Combination Therapy 100%
• Drug-eluting 100%
• Embolic Microspheres 100%
• Synergistic Therapy 100%
• Tirapazamine 100%
• Transarterial 100%
• Advanced Stage 50%
• Poor Prognosis 50%
• Hepatocellular Carcinoma 50%
• Hepatoblastoma 50%
• Tumor Growth 50%
• Blockage 50%
• Liver 50%
• Tumor 50%
• Hypoxia 50%
• Drug Concentration 50%
• Microenvironment 50%
• Occlusion 50%
• Target Organ 50%
• Chemotherapy 50%
• Liver Cancer Cell Lines 50%
• Porous Particles 50%
• Polymer Microspheres 50%
• Blood Supply 50%
• Treatment Outcome 50%
• Therapeutic Outcome 50%
• Efficacy Study 50%
• Angiogenic 50%
• Liver Tumor Model 50%
• Tissue Stress 50%
• Tissue Necrosis 50%
• Recurrence Rate 50%
• Degradable 50%
• Tumor Site 50%
• Antiproliferation 50%
• Biodistribution Studies 50%
• Non-porous 50%
• Porous Microspheres 50%
• Intratumor 50%
• Synergic 50%
• Drug Exposure 50%
• Hepatic Artery 50%
• Transarterial Chemoembolization 50%
• Orthotopic Liver Cancer 50%
• Drug Perfusion 50%
• Hypoxia-activated Prodrug 50%
• Unresectable Hepatocellular Carcinoma 50%
• Safety Study 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Liver Cancer 100%
• Microsphere 100%
• Liver Cell Carcinoma 75%
• Neoplasm 50%
• Doxorubicin 50%
• Combination Therapy 50%
• Hypoxia 50%
• Tirapazamine 50%
• Tumor Growth 25%
• Chemotherapy 25%
• Cancer Model 25%
• Drug Concentration 25%
• Biodistribution 25%
• Recurrence Risk 25%
• Prodrug 25%
• Tissue Necrosis 25%